Cargando…

Selective interleukin-1 receptor–associated kinase 4 inhibitors for the treatment of autoimmune disorders and lymphoid malignancy

Pathological activation of the Toll-like receptor signaling adaptor protein MYD88 underlies many autoimmune and inflammatory disease states. In the activated B cell–like (ABC) subtype of diffuse large B cell lymphoma (DLBCL), the oncogenic MYD88 L265P mutation occurs in 29% of cases, making it the m...

Descripción completa

Detalles Bibliográficos
Autores principales: Kelly, Priscilla N., Romero, Donna L., Yang, Yibin, Shaffer, Arthur L., Chaudhary, Divya, Robinson, Shaughnessy, Miao, Wenyan, Rui, Lixin, Westlin, William F., Kapeller, Rosana, Staudt, Louis M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Rockefeller University Press 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4689168/
https://www.ncbi.nlm.nih.gov/pubmed/26621451
http://dx.doi.org/10.1084/jem.20151074
_version_ 1782406805739012096
author Kelly, Priscilla N.
Romero, Donna L.
Yang, Yibin
Shaffer, Arthur L.
Chaudhary, Divya
Robinson, Shaughnessy
Miao, Wenyan
Rui, Lixin
Westlin, William F.
Kapeller, Rosana
Staudt, Louis M.
author_facet Kelly, Priscilla N.
Romero, Donna L.
Yang, Yibin
Shaffer, Arthur L.
Chaudhary, Divya
Robinson, Shaughnessy
Miao, Wenyan
Rui, Lixin
Westlin, William F.
Kapeller, Rosana
Staudt, Louis M.
author_sort Kelly, Priscilla N.
collection PubMed
description Pathological activation of the Toll-like receptor signaling adaptor protein MYD88 underlies many autoimmune and inflammatory disease states. In the activated B cell–like (ABC) subtype of diffuse large B cell lymphoma (DLBCL), the oncogenic MYD88 L265P mutation occurs in 29% of cases, making it the most prevalent activating mutation in this malignancy. IRAK4 kinase accounts for almost all of the biological functions of MYD88, highlighting IRAK4 as a therapeutic target for diseases driven by aberrant MYD88 signaling. Using innovative structure-based drug design methodologies, we report the development of highly selective and bioavailable small molecule IRAK4 inhibitors, ND-2158 and ND-2110. These small molecules suppressed LPS-induced TNF production, alleviated collagen-induced arthritis, and blocked gout formation in mouse models. IRAK4 inhibition promoted killing of ABC DLBCL lines harboring MYD88 L265P, by down-modulating survival signals, including NF-κB and autocrine IL-6/IL-10 engagement of the JAK–STAT3 pathway. In ABC DLBCL xenograft models, IRAK4 inhibition suppressed tumor growth as a single agent, and in combination with the Bruton’s tyrosine kinase (BTK) inhibitor ibrutinib or the Bcl-2 inhibitor ABT-199. Our findings support pharmacological inhibition of IRAK4 as a therapeutic strategy in autoimmune disorders, in a genetically defined population of ABC DLBCL, and possibly other malignancies dependent on aberrant MYD88 signaling.
format Online
Article
Text
id pubmed-4689168
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher The Rockefeller University Press
record_format MEDLINE/PubMed
spelling pubmed-46891682016-06-14 Selective interleukin-1 receptor–associated kinase 4 inhibitors for the treatment of autoimmune disorders and lymphoid malignancy Kelly, Priscilla N. Romero, Donna L. Yang, Yibin Shaffer, Arthur L. Chaudhary, Divya Robinson, Shaughnessy Miao, Wenyan Rui, Lixin Westlin, William F. Kapeller, Rosana Staudt, Louis M. J Exp Med Research Articles Pathological activation of the Toll-like receptor signaling adaptor protein MYD88 underlies many autoimmune and inflammatory disease states. In the activated B cell–like (ABC) subtype of diffuse large B cell lymphoma (DLBCL), the oncogenic MYD88 L265P mutation occurs in 29% of cases, making it the most prevalent activating mutation in this malignancy. IRAK4 kinase accounts for almost all of the biological functions of MYD88, highlighting IRAK4 as a therapeutic target for diseases driven by aberrant MYD88 signaling. Using innovative structure-based drug design methodologies, we report the development of highly selective and bioavailable small molecule IRAK4 inhibitors, ND-2158 and ND-2110. These small molecules suppressed LPS-induced TNF production, alleviated collagen-induced arthritis, and blocked gout formation in mouse models. IRAK4 inhibition promoted killing of ABC DLBCL lines harboring MYD88 L265P, by down-modulating survival signals, including NF-κB and autocrine IL-6/IL-10 engagement of the JAK–STAT3 pathway. In ABC DLBCL xenograft models, IRAK4 inhibition suppressed tumor growth as a single agent, and in combination with the Bruton’s tyrosine kinase (BTK) inhibitor ibrutinib or the Bcl-2 inhibitor ABT-199. Our findings support pharmacological inhibition of IRAK4 as a therapeutic strategy in autoimmune disorders, in a genetically defined population of ABC DLBCL, and possibly other malignancies dependent on aberrant MYD88 signaling. The Rockefeller University Press 2015-12-14 /pmc/articles/PMC4689168/ /pubmed/26621451 http://dx.doi.org/10.1084/jem.20151074 Text en This article is distributed under the terms of an Attribution–Noncommercial–Share Alike–No Mirror Sites license for the first six months after the publication date (see http://www.rupress.org/terms). After six months it is available under a Creative Commons License (Attribution–Noncommercial–Share Alike 3.0 Unported license, as described at http://creativecommons.org/licenses/by-nc-sa/3.0/).
spellingShingle Research Articles
Kelly, Priscilla N.
Romero, Donna L.
Yang, Yibin
Shaffer, Arthur L.
Chaudhary, Divya
Robinson, Shaughnessy
Miao, Wenyan
Rui, Lixin
Westlin, William F.
Kapeller, Rosana
Staudt, Louis M.
Selective interleukin-1 receptor–associated kinase 4 inhibitors for the treatment of autoimmune disorders and lymphoid malignancy
title Selective interleukin-1 receptor–associated kinase 4 inhibitors for the treatment of autoimmune disorders and lymphoid malignancy
title_full Selective interleukin-1 receptor–associated kinase 4 inhibitors for the treatment of autoimmune disorders and lymphoid malignancy
title_fullStr Selective interleukin-1 receptor–associated kinase 4 inhibitors for the treatment of autoimmune disorders and lymphoid malignancy
title_full_unstemmed Selective interleukin-1 receptor–associated kinase 4 inhibitors for the treatment of autoimmune disorders and lymphoid malignancy
title_short Selective interleukin-1 receptor–associated kinase 4 inhibitors for the treatment of autoimmune disorders and lymphoid malignancy
title_sort selective interleukin-1 receptor–associated kinase 4 inhibitors for the treatment of autoimmune disorders and lymphoid malignancy
topic Research Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4689168/
https://www.ncbi.nlm.nih.gov/pubmed/26621451
http://dx.doi.org/10.1084/jem.20151074
work_keys_str_mv AT kellypriscillan selectiveinterleukin1receptorassociatedkinase4inhibitorsforthetreatmentofautoimmunedisordersandlymphoidmalignancy
AT romerodonnal selectiveinterleukin1receptorassociatedkinase4inhibitorsforthetreatmentofautoimmunedisordersandlymphoidmalignancy
AT yangyibin selectiveinterleukin1receptorassociatedkinase4inhibitorsforthetreatmentofautoimmunedisordersandlymphoidmalignancy
AT shafferarthurl selectiveinterleukin1receptorassociatedkinase4inhibitorsforthetreatmentofautoimmunedisordersandlymphoidmalignancy
AT chaudharydivya selectiveinterleukin1receptorassociatedkinase4inhibitorsforthetreatmentofautoimmunedisordersandlymphoidmalignancy
AT robinsonshaughnessy selectiveinterleukin1receptorassociatedkinase4inhibitorsforthetreatmentofautoimmunedisordersandlymphoidmalignancy
AT miaowenyan selectiveinterleukin1receptorassociatedkinase4inhibitorsforthetreatmentofautoimmunedisordersandlymphoidmalignancy
AT ruilixin selectiveinterleukin1receptorassociatedkinase4inhibitorsforthetreatmentofautoimmunedisordersandlymphoidmalignancy
AT westlinwilliamf selectiveinterleukin1receptorassociatedkinase4inhibitorsforthetreatmentofautoimmunedisordersandlymphoidmalignancy
AT kapellerrosana selectiveinterleukin1receptorassociatedkinase4inhibitorsforthetreatmentofautoimmunedisordersandlymphoidmalignancy
AT staudtlouism selectiveinterleukin1receptorassociatedkinase4inhibitorsforthetreatmentofautoimmunedisordersandlymphoidmalignancy